Medical News

RSS

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

Hypothyroidism linked to COPD exacerbation risk

Research shows that chronic obstructive pulmonary disease patients with hypothyroidism have an elevated exacerbation frequency but, despite this, experience similar quality of life to patients with normal thyroid function.

8 Oct 2013

Bipolar disorder ‘distinct’ from borderline personality disorder

Researchers say that there are clear clinical differences between depressed patients with bipolar II disorder and those with borderline personality disorder, which supports the two being treated as distinct conditions.

8 Oct 2013

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Motivational interviewing may help specific subgroups of patients with schizophrenia to adhere to their antipsychotic medication, a study suggests.

8 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

Forma Achieves First Milestone In Celgene Collaboration

...

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Clinical Genomics Nabs Enterix, Aims To Launch New Bowel Cancer Blood Test

...

8 Oct 2013

A window to the brain: an interview with Professor Guillermo Aguilar, UC Riverside's Bourns College of Engineering (BCOE)

It is literally a transparent window made of yttria-stabilized zirconia (YSZ), which we envision to become a suitable cranial implant that allows physicians for optical access to the tissue brain. It would serve the same mechanical function of current cranial implants made of other materials, such as titanium, except that it would enable optical access too, which could be very beneficial for post-operatory diagnostic or therapeutic procedures.

8 Oct 2013

Horizon Medicare beneficiaries to receive pharmacy services through Prime Therapeutics

Beginning January 1, 2014, Horizon Healthcare Services, Inc. Medicare beneficiaries will receive pharmacy services through Prime Therapeutics LLC. Prime began providing pharmacy benefit management services to the plan's commercial members July 1, 2013.

8 Oct 2013

MedShape closes $11 million in new financing

MedShape, Inc., the industry leader in shape memory orthopedic devices, today announced the closing of $11 million in new financing. The investment will help drive further development and commercialization of pipeline products, including the full market release of the Eclipse Soft Tissue Anchor, MedShape's newest shape memory fixation device for soft tissue repair.

8 Oct 2013

Metastatic site impacts survival in targeted RCC treatment

Bone and liver metastases may have the heaviest impact on the survival of patients receiving targeted therapy for metastatic renal cell carcinoma, suggest data from the International Metastatic Renal Cell Carcinoma Database Consortium.

8 Oct 2013

PSA mass ratio shows prognostic power in localized prostate cancer

Research shows that pathologic prostate-specific antigen mass ratio is a significant predictor for biochemical recurrence-free survival following radical prostatectomy for localized prostate cancer in patients with negative surgical resection margins.

8 Oct 2013